NervGen Pharma Corp (NGENF OTCQB) stock market data APIs
$2.6005
-0.05(-1.9%)
as of June 18, 2025
Try our APIs with
free plan!
NervGen Pharma Corp Financial Data Overview
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Prev. Close
2.6005
Open
2.5532
High
2.627
Low
2.5532
52 wk Range
1.46-5.1
Market Cap
186 M
Shares Outstanding
71 935 K
EPS
-0.0389
Beta
0.596
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NervGen Pharma Corp data using free add-ons & libraries
Get NervGen Pharma Corp Fundamental Data
NervGen Pharma Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -25 960 776
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NervGen Pharma Corp News
New
Catalyst Watch: Crypto buzz with the Circle IPO, Snowflake event and the May Jobs Report
[Stock market Exchanges Volume Leaders Digital Tableau interface background] bestsale Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. ...
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury "The ability of...
NervGen Pharma Applauds President Biden Signing Defense Bill
Department of Defense now able to Move Forward on Brain Plasticity Research Cincinnati, Ohio--(Newsfile Corp. - January 4, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) through its subsid...
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
